Dementia With Lewy Bodies
95
21
28
47
Key Insights
Highlights
Success Rate
94% trial completion (above average)
Published Results
15 trials with published results (16%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
3.2%
3 terminated out of 95 trials
94.0%
+7.5% vs benchmark
8%
8 trials in Phase 3/4
32%
15 of 47 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 47 completed trials
Clinical Trials (95)
RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
Ambroxol in New and Early DLB, A Phase IIa Multicentre Randomized Controlled Double Blind Clinical Trial
Studies of Brain and Body Interaction
Neurological Soft Signs in Neurodegenerative Dementias
Cognitive Stimulation Therapy for Dementia: A Two-Armed Pragmatic Trial
PERSEVERE: Peer Mentor Support and Caregiver Education in Lewy Body Dementia
[18F]F-DOPA Imaging in Patients With Autonomic Failure
Terazosin for Dementia With Lewy Bodies
Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies
Community Outreach for Palliative Engagement -- Parkinson Disease
Elucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia
The PACE-DLB Study
In Vivo PET of Synaptic Density in Cognitive Disorders
PET Imaging Evaluation of [11C]SY08
Family Caregiver Online Survey (Dementia and Swallowing Difficulties)
Palliative Care for Persons With Late-stage Alzheimer's and Related Dementias and Their Caregivers
Expanded Access Program for CT1812 (Zervimesine)
Improving Prognostic Confidence in Neurodegenerative Diseases Causing Dementia Using Peripheral Biomarkers and Integrative Modeling
Exploration of GCase Activity to Identify a Subpopulation Eligible for a Therapeutic Trial in Dementia With Lewy Bodies
Self and Autobiographical Memory in Dementia With Lewy Bodies and Alzheimer Disease: a Behavioral and Multimodal Neuroimaging Study